A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results.

Keywords

Medicine, Cardiology, Internal medicine, Coronary heart disease, Secondary prevention

References

No references recorded for this paper.

Cited by

• Guidelines--a missed opportunity.Mauro Sergio dos Santos Mendes — 1999
• Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study).Esteban Vélez Camarero — 2000
• Dietary prevention of sudden cardiac death.M. de Lorgeril — 2002
• Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from the nationwide French PREVENIR surveyRichard C. San George, Henry D. Hoberman — 2002
• C-reactive protein--to screen or not to screen?Giorgio Dell'Orefice — 2002
• Prevalence of left ventricular diastolic dysfunction in the community. Results from a Doppler echocardiographic-based survey of a population sample.Оксана Александровна Степанова, Людмила Александровна Алтынникова, Елена Ивановна Минакова — 2003
• The CEPHEUS Pan-Asian survey: high low-density lipoprotein cholesterol goal attainment rate among hypercholesterolaemic patients undergoing lipid-lowering treatment in a Hong Kong regional centre.Raymond Hon-Wah Chan, Pang-Fai Chan, Kelvin Chan — 2012
• Control of baseline cardiovascular risk factors in the SU-FOL-OM3 study cohort: does the localization of the arterial event matter?Claire Vesin, Pilar Galán, Benoît Gautier — 2010
• German nationwide data on current trends and management of acute myocardial infarction: discrepancies between trials and real-life.Araceli del Moral Hernández — 2014
• Patterns of statin prescription in acute myocardial infarction: the French registry of Acute ST-elevation or non-ST-elevation Myocardial Infarction (FAST-MI).Jean Ferrières, Vincent Bataille, Florence Leclercq — 2009
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group — 1998
• Second Manifestations of ARTerial disease (SMART) study: Rationale and designPetra C. G. Simons, Ale Algra, Marielle F van de Laak — 1999
• CLINICAL RATIONALE FOR ROSUVASTATIN, A POTENT NEW HMG‐COA REDUCTASE INHIBITORM Hanefeld — 2001
• The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.Erland Erdmann, John Dormandy, B Charbonnel — 2007
• Addressing a Treatment GapJonathan L. Isaacsohn, Jonathan A. Tobert, Amy O. Johnson‐Levonas — 2002
• Lipid-Modifying Therapy and Attainment of Cholesterol Goals in HungaryGy. Paragh, L??szlo M??rk, K??roly Z??molyi — 2007
• A Data Mining Model to predict and analyze the events related to Coronary Heart Disease using Decision Trees with Particle Swarm Optimization for Feature SelectionA. Sheik Abdullah — 2012
• Entraînement physique en réadaptation cardiaqueMichel Lamotte — 2010
• Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008: Basado en el Documento del Cuarto Grupo de Trabajo Conjunto de la Sociedad Europea de Cardiología y otras sociedades científicasJosé María Lobos Bejarano, Miguel Ángel Royo‐Bordonada, Carlos Brotons Cuixart — 2009
• New Information on the Role of Beta-Blockers in Cardiac TherapyAnders Himmelmänn — 1999

Related papers

• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group — 1998
• Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme.2001
• Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention.Second Joint Task Force of European — 1998
• The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.Frank M. Sacks, Marc A. Pfeffer, Lemuel A. Moyé — 1996
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)Anders Olsson, John J.V. McMurray, G Thorgeirsson — 1994
• Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. 1995.James Shepherd, Stuart M. Cobbe, Ian Ford — 2004
• European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.G De Backer — 2003
• The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.Thomas A. Pearson, Irene Laurora, Henry Chu — 2000
• Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.John R. Downs, Michael Clearfield, Stephen E. Weis — 1998